By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AiCuris 

Friedrich-Ebert-Str. 475
Building 302
Wuppertal    D-42117  Germany
Phone: 49-0-202-31763-0 Fax: 49-0-202-31763-1177


SEARCH JOBS


Industry
Pharmaceutical






Company News
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014 10:54:18 AM
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir 1/29/2013 10:55:50 AM
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/30/2012 1:02:13 PM
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in Preparation for Phase III 8/7/2012 10:39:46 AM
Results of AiCuris's Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants Meeting Both Primary Efficacy Endpoints to be Presented at International Conferences 4/2/2012 9:50:12 AM
AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients 2/14/2012 9:50:00 AM
AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA 1/5/2012 9:32:17 AM
AiCuris: No Resistant Herpes Simplex Virus (HSV) Observed in Phase II Trial with Herpes Drug AIC316 9/6/2011 11:15:58 AM
AiCuris' HCMV Drug Letermovir (AIC246) Receives Fast Track from FDA, New Data to be Presented at 51st ICAAC 8/29/2011 9:08:41 AM
AiCuris' Novel HSV Compound AIC316 Shows Efficacy in Phase II 7/18/2011 9:34:36 AM
12
//-->